Introduction
Preeclampsia (PE), which affects approximately 2% of pregnancies, is a major cause of maternal and perinatal morbidity and death. 1, 2 The underlying mechanism for early-PE, requiring delivery before 34 weeks, is thought to be impaired placentation because of inadequate trophoblastic invasion of the maternal spiral arteries, which has been documented by the findings of both histologic and Doppler ultrasound studies of the uterine arteries, [3] [4] [5] [6] [7] [8] reduced maternal serum concentration of the placental product pregnancy-associated plasma protein-A (PAPP-A) 9 and impaired fetal growth. 10 In contrast late-PE, which is usually associated with normal placentation and fetal growth, 11, 12 is thought to be a manifestation of an underlying metabolic disorder with increased insulin resistance. [13] [14] [15] Insulin-like growth factor-binding protein 3 (IGFBP-3) belongs to the family of IGFBPs, which determine the bioavailability and activity of the IGFs. 16, 17 In the circulation, IGFBP-3 binds to approximately 95% of IGF-I and IGF-II and this complex prolongs the half-life of IGFs and protects them from degradation. [16] [17] [18] [19] An endogenous pregnancy-related IGFBP-3 proteolytic activity is considered a fundamental mechanism to increase the bioavailability of IGF-I, [20] [21] [22] which is a mitogenic polypeptide that stimulates cellular proliferation and differentiation and is involved in the regulation of trophoblast invasion and placental development. [23] [24] [25] In addition, IGFBP-3 can inhibit cell proliferation and stimulate apoptosis via non-IGFdependent pathways. 16, 26 Thus, IGFBP-3 has important roles in regulating many aspects of placental development and fetal growth. 17, 27, 28 There is contradictory evidence regarding maternal serum levels of IGFBP-3 in pregnancies with PE with some studies reporting a decrease 29, 30 and others no significant difference compared with controls. [31] [32] [33] The aims of our study were first, to investigate the maternal serum concentrations of IGFBP-3 at 11-13 weeks in pregnancies that subsequently develop PE and second, to examine the possible association with uterine artery pulsatility index (PI) and maternal serum PAPP-A, which reflect early placental perfusion and function and are altered in pregnancies that subsequently develop PE. 7, 9 
Methods

Study population
This was a case-control study drawn from a large observational prospective study for hypertensive complications of pregnancy in women attending for their routine first hospital visit in pregnancy at King's College Hospital, London, UK. In this visit, which is held at 11 þ 0 -13 þ 6 weeks of gestation, all women have an ultrasound scan to first, confirm gestational age from the measurement of the fetal crown-rump length, second, diagnose any major fetal abnormalities and third, measure fetal nuchal translucency thickness as part of screening for chromosomal abnormalities. In addition, the maternal serum PAPP-A and free b-human chorionic gonadotropin are determined and the results are combined with the fetal nuchal translucency to calculate the patient-specific risk for trisomy 21. 34, 35 We recorded maternal characteristics and medical history, stored serum at À80 1C for subsequent biochemical analysis and performed transabdominal pulsed Doppler for measurement of the left and right uterine artery PI and recorded the mean value. 7 Written informed consent was obtained from the women agreeing to participate in the study, which was approved by King's College Hospital Ethics Committee.
Maternal serum from 20 cases that developed PE requiring delivery before 34 weeks (early-PE) and 40 cases that developed late-PE were selected at random from cases with available stored serum. Each case of PE was matched with two controls who had blood collected on the same date and delivered a phenotypically normal neonate appropriate for gestational age at term and did not develop any hypertensive disorder of pregnancy. None of the samples in the case-control study were previously thawed and refrozen.
Maternal history
Patients were asked to complete a questionnaire on maternal age, racial origin (Caucasian, African, South Asian, East Asian and Mixed), cigarette smoking during pregnancy (yes or no), method of conception (spontaneous or use of ovulation induction drugs), history of chronic hypertension (yes or no), parity (parous or nulliparous if no delivery beyond 23 weeks), obstetric history (including a previous pregnancy with PE) and history of PE in the mother (yes or no). The questionnaire was then reviewed by a doctor together with the patient. The maternal weight and height were measured and the body mass index was calculated in kg m -2 .
Outcome measures
The definition of PE was that of the International Society for the Study of Hypertension in Pregnancy. 36 The systolic blood pressure should be 140 mm Hg or more and/or the diastolic blood pressure should be 90 mm Hg or more on at least two occasions 4 h apart developing after 20 weeks of gestation together with significant proteinuria in previously normotensive women. Significant proteinuria is defined by 300 mg or more in 24 h or two readings of at least þ þ on dipstick analysis of midstream or catheter urine specimens if no 24-h collection is available. In PE superimposed on chronic hypertension, significant proteinuria (as defined above) should develop after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or the presence of hypertension at the booking visit before 20 weeks of gestation in the absence of trophoblastic disease).
Sample analysis
Serum samples were used to measure IGFBP-3 concentration by a quantitative enzyme-linked immunosorbent assay technique using DSL-10-IGFBP-3 assay (Diagnostic Systems Laboratories, Inc., Webster, TX, USA). The lower limit of detection of the assays for IGFBP-3 was 0.04 ng ml -1 .
Literature search
We searched MEDLINE and EMBASE from 1996 to September 2010 to identify studies reporting on the relationship between maternal circulating IGFBP-3 and PE.
Statistical analysis
The following steps were taken for the statistical analysis. The distribution of IGFBP-3 was Gaussian as demonstrated by probability plots and ShapiroWilk test. In the unaffected group, multiple regression analysis was used to determine which of the factors among the maternal characteristics and gestation were significant predictors of IGFBP-3. Each value in the unaffected and PE groups was then converted into multiple of the unaffected median (MoM) after adjustment for those characteristics found to be significant in the multiple regression analysis. Similarly, the measured uterine artery PI and maternal serum PAPP-A were converted into MoMs after adjustment for gestation, maternal age, maternal weight, smoking status, parity, method of conception and racial origin. 
Results
The maternal characteristics of the outcome groups are compared in Table 1 . In the groups that developed PE, compared with the unaffected group, there were more women of African racial origin, more women had PE in a previous pregnancy, had chronic hypertension and delivered neonates with a lower birth weight percentile. In the early-PE group, women were younger and in the late-PE group they were heavier.
Multiple regression analysis in the unaffected group demonstrated that for serum IGFBP-3, significant independent contributions were provided by fetal crown-rump length and use of ovulation induction drugs but not by racial origin (P ¼ 0.838), maternal age (P ¼ 0.259), maternal weight (P ¼ 0.136), smoking status (P ¼ 0.097) or parity (P ¼ 0.486):
Expected IGFBP-3 ¼ 76.086-0.283 Â fetal crownrump length in mm þ (À7.617 if use of ovulation induction drugs, 0 if spontaneous conception);
In the PE group, compared with the unaffected group, the median IGFBP-3 MoM (1.12 vs 1.00, Po0.0001) and uterine artery PI MoM (1.28 vs 1.00, P ¼ 0.001) were increased and serum PAPP-A MoM (0.79 vs 1.00, P ¼ 0.005) was decreased. The maternal serum concentration of IGFBP-3 was significantly higher in late-PE than in controls (1.16 vs 1.00 MoM, Po0.0001) but not in early-PE (1.07 vs 1.00, P ¼ 0.169). In early-PE compared with controls, uterine artery PI MoM was significantly higher (1.41 vs 1.00, Po0.0001) and PAPP-A MoM was significantly lower (0.53 vs 1.00, P ¼ 0.002) but in late-PE compared with controls, there were no significant differences in uterine artery PI MoM (1.11 vs 1.00, P ¼ 0.075) and PAPP-A MoM (0.87 vs 1.00, P ¼ 0.102) ( Table 2 ).
In the group that developed PE there was no significant association of serum IGFBP-3 with either uterine artery PI (r ¼ À0.038, P ¼ 0.775), maternal serum PAPP-A (r ¼ 0.143, P ¼ 0.275) or birth weight percentile (r ¼ 0.163, P ¼ 0.215) but there was a significant association with gestation at delivery (r ¼ 0.308, P ¼ 0.017). There was a significant association of uterine artery PI with both gestation at delivery (r ¼ À0.379, P ¼ 0.003) and birth weight percentile (r ¼ À0.337, P ¼ 0.008). There was a significant association of maternal serum PAPP-A with gestation at delivery (r ¼ 0.321, P ¼ 0.012) but not with birth weight percentile (r ¼ 0.130,
The data from studies identified by the literature search are summarized in Table 3 . In two of the four studies examining samples from pregnancies with IGFBP-3 at 11-13 weeks in preeclampsia S Sifakis et al the clinical signs of PE, serum IGFBP-3 was lower in PE than in controls and in the other two studies there were no significant differences between the groups. In the one study examining samples obtained before the clinical onset of PE, there were no significant differences in serum IGFBP-3 between cases and controls.
Discussion
The findings of this study demonstrate that at 11-13 weeks' gestation in pregnancies destined to develop PE compared with unaffected controls, the median maternal serum IGFBP-3 and uterine artery PI are higher and serum PAPP-A is lower. The uterine artery PI was significantly higher and maternal serum PAPP-A was significantly lower in early but not late-PE whereas serum IGFBP-3 MoM was significantly higher in late but not in early-PE. There was no significant association between IGFBP-3 with either uterine artery PI or serum PAPP-A. These findings suggest that IGFBP-3 may be implicated in the pathogenesis of PE in a manner unrelated to impaired placental perfusion and function.
The maternal characteristics of the pregnancies that developed PE, compared with unaffected controls, are compatible with the results of previous screening studies demonstrating a higher risk for women of African racial origin and those with chronic hypertension and a history of PE in a previous pregnancy. 38 Similarly, the association between early-PE with high uterine artery PI and low serum PAPP-A is compatible with findings of extensive studies implicating impaired placental development and function in the pathogenesis of early-PE. [7] [8] [9] In the unaffected controls, the maternal serum concentration of IGFBP-3 decreased with fetal crown-rump length and was lower in women using ovulation induction drugs. Consequently, the measured concentration of IGFBP-3 in maternal serum was adjusted for these factors before comparing with pathological pregnancies. None of the previous studies made any adjustments for possible confounding factors that may affect the circulating IGFBP-3 concentration. [29] [30] [31] [32] [33] In pregnancies that subsequently developed PE maternal serum IGFBP-3 was increased. This finding contradicts the results of previous studies, which reported that in established disease the levels are either decreased or not altered. A possible explanation for this difference is that in pregnancies that will develop PE the levels in the first-trimester are increased but with advancing gestation they normalize or even decrease. Such difference in the pattern of circulating levels between the first-and third-trimesters of pregnancy in pregnancies with PE have also been reported for PAPP-A, which is low in the first-trimester but increased at the time of the clinical onset of PE. 8, 39, 40 Another possible explanation for the differences in our findings from previous reports is the method used IGFBP-3 at 11-13 weeks in preeclampsia S Sifakis et al for measurement of IGFBP-3, which was by enzymelinked immunosorbent assay in our study and by radioimmunoassay in the previous studies. Unlike enzyme-linked immunosorbent assay, the radioimmunoassays do not distinct between the intact and proteolysed forms IGFBP-3 and consequently do not reflect the concentration of IGFBP-3 capable of sequestering IGFs in the bloodstream. 41, 42 Evidence from both in vitro and in vivo studies suggest that increased levels of IGFBP-3 are associated with hyperglycaemia, metabolic syndrome and increased insulin resistance. [43] [44] [45] [46] Consequently, our finding of an increase in serum IGFBP-3 from the first-trimester of pregnancy in cases that subsequently develop late-PE appears to provide further evidence in support of the association between increased insulin resistance and late-PE.
